Incidence of symptomatic Borrelia burgdorferi sensu lato infection in Romania, 2018-2023.
Disease burden
Epidemiology
Lyme borreliosis
Tick-borne disease
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
12
06
2024
accepted:
13
08
2024
medline:
6
9
2024
pubmed:
6
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), is the most common tick-borne disease in Europe. Although public health surveillance for LB has been conducted in Romania since 2007, the extent of under-detection of Bbsl infections by LB surveillance has not been estimated. We therefore estimated the under-detection of symptomatic Bbsl infections by LB surveillance to better understand the LB burden in Romania. The number of incident symptomatic Bbsl infections were estimated from a seroprevalence study conducted in six counties (population 2.3 M) and estimates of the symptomatic proportion and duration of persistence of anti-Bbsl immunoglobulin G (IgG) antibodies. The number of incident symptomatic Bbsl infections were compared with the number of surveillance-reported LB cases to derive an under-detection multiplier, and then the under-detection multiplier was applied to LB surveillance data to estimate the incidence of symptomatic Bbsl infection from 2018 to 2023. We estimate that there were 1968 individuals with incident symptomatic Bbsl infection in the six counties where the seroprevalence study was conducted in 2020, compared with the 187 surveillance-reported LB cases, resulting in an under-detection multiplier of 10.5 (i.e., for every surveillance-reported LB case, there were 10.5 symptomatic incident Bbsl infections). The incidence of symptomatic Bbsl infection in the six counties was 86.9/100,000 population in 2023, similar to the incidence in 2018-2020 (86.0) and higher than in 2021-2022 (40.3). There is a higher incidence of symptomatic Bbsl infection than is reported through public health surveillance for LB in Romania. Additional efforts are needed to strengthen disease prevention and address the important public health problem of LB.
Sections du résumé
BACKGROUND
BACKGROUND
Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), is the most common tick-borne disease in Europe. Although public health surveillance for LB has been conducted in Romania since 2007, the extent of under-detection of Bbsl infections by LB surveillance has not been estimated. We therefore estimated the under-detection of symptomatic Bbsl infections by LB surveillance to better understand the LB burden in Romania.
METHODS
METHODS
The number of incident symptomatic Bbsl infections were estimated from a seroprevalence study conducted in six counties (population 2.3 M) and estimates of the symptomatic proportion and duration of persistence of anti-Bbsl immunoglobulin G (IgG) antibodies. The number of incident symptomatic Bbsl infections were compared with the number of surveillance-reported LB cases to derive an under-detection multiplier, and then the under-detection multiplier was applied to LB surveillance data to estimate the incidence of symptomatic Bbsl infection from 2018 to 2023.
RESULTS
RESULTS
We estimate that there were 1968 individuals with incident symptomatic Bbsl infection in the six counties where the seroprevalence study was conducted in 2020, compared with the 187 surveillance-reported LB cases, resulting in an under-detection multiplier of 10.5 (i.e., for every surveillance-reported LB case, there were 10.5 symptomatic incident Bbsl infections). The incidence of symptomatic Bbsl infection in the six counties was 86.9/100,000 population in 2023, similar to the incidence in 2018-2020 (86.0) and higher than in 2021-2022 (40.3).
CONCLUSIONS
CONCLUSIONS
There is a higher incidence of symptomatic Bbsl infection than is reported through public health surveillance for LB in Romania. Additional efforts are needed to strengthen disease prevention and address the important public health problem of LB.
Identifiants
pubmed: 39238048
doi: 10.1186/s13071-024-06449-5
pii: 10.1186/s13071-024-06449-5
doi:
Substances chimiques
Antibodies, Bacterial
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
378Informations de copyright
© 2024. The Author(s).
Références
Stanek G, Wormser G, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461–73. https://doi.org/10.1016/S0140-6736(11)60103-7 .
doi: 10.1016/S0140-6736(11)60103-7
pubmed: 21903253
Burn L, Tran TMP, Pilz A, Vyse A, Fletcher MA, Angulo FJ, et al. Incidence of Lyme Borreliosis in Europe from National Surveillance systems (2005–2020). Vector Borne Zoonotic Dis Larchmt N. 2023;23:156–71. https://doi.org/10.1089/vbz.2022.0071 .
doi: 10.1089/vbz.2022.0071
van den Wijngaard CC, Hofhuis A, Simões M, Rood E, van Pelt W, Zeller H, et al. Surveillance perspective on Lyme borreliosis across the European Union and European Economic Area. Euro Surveill. 2017;22:30569. https://doi.org/10.2807/1560-7917.ES.2017.22.27.30569 .
doi: 10.2807/1560-7917.ES.2017.22.27.30569
pubmed: 28703098
pmcid: 5508331
Centrul Național de Supraveghere şi Control al Bolilor Transmisibile-Boala Lyme. Available online: http://www.cnscbt.ro/index.php/analiza-date-supraveghere/boala-lyme-1?limit=10&limitstart=0 . Accessed 1 May 2024.
Gibbons CL, Mangen MJJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 2014;14:147. https://doi.org/10.1186/1471-2458-14-147 .
doi: 10.1186/1471-2458-14-147
pubmed: 24517715
pmcid: 4015559
Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, et al. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis. 2009;15:2004–7. https://doi.org/10.3201/eid1512.091413 .
doi: 10.3201/eid1512.091413
pubmed: 19961687
pmcid: 3375879
Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17:7–15. https://doi.org/10.3201/eid1701.p11101 .
doi: 10.3201/eid1701.p11101
pubmed: 21192848
pmcid: 3375761
Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, symptomatic infections, hospitalizations, and deaths using seroprevalence surveys. JAMA Netw Open. 2021;4:e2033706. https://doi.org/10.1001/jamanetworkopen.2020.33706 .
doi: 10.1001/jamanetworkopen.2020.33706
pubmed: 33399860
pmcid: 7786245
Tilea B, Tripon G, Septimiu V, Tilea I. Serological, clinical and epidemiological aspects of Lyme borreliosis in Mures County, Romania. Rom Rev Lab Med. 2014;1:22. https://doi.org/10.2478/rrlm-2014-0020 .
doi: 10.2478/rrlm-2014-0020
Briciu V, Flonta M, Leucuța D, Lupșe M. The diagnostic challenges and clinical and serological outcome in patients hospitalized for suspected lyme neuroborreliosis. Microorganisms. 2022;10:1392. https://doi.org/10.3390/microorganisms10071392 .
doi: 10.3390/microorganisms10071392
pubmed: 35889111
pmcid: 9324737
Burn L, Pilz A, Vyse A, Gutiérrez Rabá AV, Angulo FJ, Tran TMP, et al. Seroprevalence of Lyme Borreliosis in Europe: results from a systematic literature review (2005–2020). Vector Borne Zoonotic Dis. 2023;23:195–220. https://doi.org/10.1089/vbz.2022.0069 .
doi: 10.1089/vbz.2022.0069
pubmed: 37071401
pmcid: 10122246
Kalmár Z, Briciu V, Coroian M, Flonta M, Rădulescu AL, Topan A, et al. Seroprevalence of antibodies against Borrelia burgdorferi sensu lato in healthy blood donors in Romania: an update. Parasit Vectors. 2021;14:596. https://doi.org/10.1186/s13071-021-05099-1 .
doi: 10.1186/s13071-021-05099-1
pubmed: 34863277
pmcid: 8645117
Fryland L, Wilhelmsson P, Lindgren PE, Nyman D, Ekerfelt C, Forsberg P. Low risk of developing Borrelia burgdorferi infection in the south-east of Sweden after being bitten by a Borrelia burgdorferi-infected tick. Int J Infect Dis. 2011;15:e174–81. https://doi.org/10.1016/j.ijid.2010.10.006 .
doi: 10.1016/j.ijid.2010.10.006
pubmed: 21168354
Wilhelmsson P, Fryland L, Lindblom P, et al. A prospective study on the incidence of Borrelia burgdorferi sensu lato infection after a tick bite in Sweden and on the Åland Islands, Finland (2008–2009). Ticks Tick Borne Dis. 2016;7:71–9. https://doi.org/10.1016/j.ttbdis.2015.08.009 .
doi: 10.1016/j.ttbdis.2015.08.009
pubmed: 26341726
Markowicz M, Schötta AM, Höss D, et al. Infections with tickborne pathogens after tick bite, Austria, 2015–2018. Emerg Infect Dis. 2021;27:1048–56. https://doi.org/10.3201/eid2704.203366 .
doi: 10.3201/eid2704.203366
pubmed: 33755546
pmcid: 8007293
Carlströmer Berthén N, Tompa E, Olausson S, et al. The AxBioTick Study: Borrelia species and tick-borne encephalitis virus in ticks, and clinical responses in tick-bitten individuals on the Aland Islands, Finland. Microorganisms. 2023;11:1100. https://doi.org/10.3390/microorganisms11051100 .
doi: 10.3390/microorganisms11051100
pubmed: 37317075
pmcid: 10223457
Faulde MK, Rutenfranz M, Hepke J, Rogge M, Görner A, Keth A. Human tick infestation pattern, tick-bite rate, and associated Borrelia burgdorferi s.l. infection risk during occupational tick exposure at the Seedorf military training area northwestern Germany. Ticks Tick Borne Dis. 2014;5:594–9. https://doi.org/10.1016/j.ttbdis.2014.04.009 .
doi: 10.1016/j.ttbdis.2014.04.009
pubmed: 24993582
Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol. 1994;32:1519–25. https://doi.org/10.1128/jcm.32.6.1519-1525.1994 .
doi: 10.1128/jcm.32.6.1519-1525.1994
pubmed: 8077398
pmcid: 264030
Hammers-Berggren S, Lebech AM, Karlsson M, Andersson U, Hansen K, Stiernstedt G. Serological follow-up after treatment of Borrelia arthritis and acrodermatitis chronica atrophicans. Scand J Infect Dis. 1994;26:339–47. https://doi.org/10.3109/00365549409011804 .
doi: 10.3109/00365549409011804
pubmed: 7939435
Lomholt H, Lebech AM, Hansen K, Brandrup F, Halkier-Sørensen L. Long-term serological follow-up of patients treated for chronic cutaneous borreliosis or culture-positive erythema migrans. Acta Derm Venereol. 2000;80:362–6. https://doi.org/10.1080/000155500459312 .
doi: 10.1080/000155500459312
pubmed: 11200835
Glatz M, Golestani M, Kerl H, Müllegger RR. Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. Arch Dermatol. 2006;142:862–8. https://doi.org/10.1001/archderm.142.7.862 .
doi: 10.1001/archderm.142.7.862
pubmed: 16847202
Tetens MM, Dessau R, Ellermann-Eriksen S, et al. The diagnostic value of serum Borrelia burgdorferi antibodies and seroconversion after Lyme neuroborreliosis, a nationwide observational study. Clin Microbiol Infect. 2022;28:1500.e1-1500.e6. https://doi.org/10.1016/j.cmi.2022.06.001 .
doi: 10.1016/j.cmi.2022.06.001
pubmed: 35709901
Westerholt M, Krogfelt KA, Dessau RB, Ocias LF. Exploring the dynamics of Borrelia burgdorferi sensu lato antibodies—a registry-based study on laboratory data from Sweden and Denmark. Clin Microbiol Infect. 2023;29:1561–6. https://doi.org/10.1016/j.cmi.2023.09.017 .
doi: 10.1016/j.cmi.2023.09.017
pubmed: 37769899
Woudenberg T, Böhm S, Böhmer M, et al. Dynamics of Borrelia burgdorferi-specific antibodies: seroconversion and seroreversion between two population-based, cross-sectional surveys among adults in Germany. Microorganisms. 2020;8:1859. https://doi.org/10.3390/microorganisms8121859 .
doi: 10.3390/microorganisms8121859
pubmed: 33255673
pmcid: 7761102
Böhm S, Woudenberg T, Stark K, et al. Seroprevalence, seroconversion and seroreversion of Borrelia burgdorferi-specific IgG antibodies in two population-based studies in children and adolescents, Germany, 2003 to 2006 and 2014 to 2017. Euro Surveill. 2023;28:2200855. https://doi.org/10.2807/1560-7917.ES.2023.28.34.2200855 .
doi: 10.2807/1560-7917.ES.2023.28.34.2200855
pubmed: 37616114
pmcid: 10451011
Olsen J, Angulo FJ, Pilz A, Halsby K, Kelly P, Turunen J, et al. Estimated number of symptomatic Lyme Borreliosis cases in adults in Finland in 2021 using seroprevalence data to adjust the number of surveillance-reported cases: a general framework for accounting for underascertainment by public health surveillance. Vector Borne Zoonotic Dis Larchmt N. 2023;23:265–72. https://doi.org/10.1089/vbz.2022.0051 .
doi: 10.1089/vbz.2022.0051
Olsen J, Angulo FJ, Pilz A, Halsby K, Kelly P, Brestrich G, et al. Estimated number of symptomatic Lyme borreliosis cases in Germany in 2021 after adjusting for under-ascertainment. Public Health. 2023;17:1–9. https://doi.org/10.1016/j.puhe.2023.03.002 .
doi: 10.1016/j.puhe.2023.03.002
Dehnert M, Fingerle V, Klier C, Talaska T, Schlaud M, Krause G, et al. Seropositivity of Lyme Borreliosis and associated risk factors: a population-based study in children and adolescents in Germany (KiGGS). PLoS ONE. 2012;7:e41321. https://doi.org/10.1371/journal.pone.0041321 .
doi: 10.1371/journal.pone.0041321
pubmed: 22905101
pmcid: 3419690
Wilking H, Fingerle V, Klier C, Thamm M, Stark K. Antibodies against Borrelia burgdorferi sensu lato among Adults, Germany, 2008–2011. Emerg Infect Dis. 2015;21:107–10. https://doi.org/10.3201/eid2101.140009 .
doi: 10.3201/eid2101.140009
pubmed: 25531140
pmcid: 4285254